PTC Therapeutics
PTCT
203 hedge funds and large institutions have $2.87B invested in PTC Therapeutics in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 80 increasing their positions, 70 reducing their positions, and 33 closing their positions.
267% more call options, than puts
Call options by funds: $56.2M | Put options by funds: $15.3M
14% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 70
3.51% more ownership
Funds ownership: 99.18% → 102.69% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 33
2% less capital invested
Capital invested by funds: $2.94B → $2.87B (-$65.5M)
1% less funds holding
Funds holding: 206 → 203 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$267M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$124M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$76.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$60.4M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$99.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$41.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$34.9M |
PTCT Hedge Fund Activity: Q1 2020 in Review
203 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2020, worth a combined $2.87B — down 2.2% from $2.94B a quarter earlier.
Fund positioning in PTCT was balanced in Q1 2020: 33 funds opened new positions, 33 closed out, 80 added to existing stakes and 70 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $267M. The largest seller was T. Rowe Price Associates, cutting an estimated $99.9M.
- 203 institutional investors held PTC Therapeutics (PTCT) as of Q1 2020, down from 206 in Q4 2019.
- Funds reported $2.87B of PTC Therapeutics stock for Q1 2020, down 2.2% quarter-over-quarter.
- 33 funds opened new PTC Therapeutics positions in Q1 2020 and 33 closed out, a net change of 0 holders.
- The largest PTC Therapeutics buyer in Q1 2020 was Wellington Management Group, an estimated $267M added.
- The largest PTC Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $99.9M sold.
Based on aggregated 13F filings for Q1 2020.